Neuroimaging outcomes for clinical trials

Journal of Nutrition, Health and Aging

Volumn 11, Issue 4, 2007, Pages 348-352

  Frisoni, G B ^a   Caroli, A ^a  

^a IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; BRAIN ATROPHY; BRAIN CORTEX; BRAIN REGION; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HIPPOCAMPUS; HUMAN; MORPHOMETRICS; NEAR INFRARED REFLECTANCE SPECTROSCOPY; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 34547147557     PISSN: 12797707     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Fox NC, Cousens S, Scahill R et al (2000) Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer Disease. Arch Neurol 57:339-344
2. Fox NC, Freeborough PA, Rossor MN (1996). Visualisation and quantification of rates of atrophy in Alzheimer's disease. Lancet 348:94-97
3. Fox NC, Black RS, Gilman S, et al (2005). Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64:1563-1572
4. Jack CR jr, Petersen RC, Xu YC, et al (1999) Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 52:1397-1403
5. Jack CR jr, Petersen RC, Xu Y et al (2000) Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 55:484-489
6. Du AT, Schuff N, Zhu XP, et al (2003) Atrophy rates of entorhinal cortex in AD and normal aging. Neurology 60:481-486
7. Lerch JP, Pruessner JC, Zijdenbos, et al (2005) Focal decline of cortical thickness in Alzheimer's disease identified by computational neuroanatomy. Cerebral cortex 15:995-1001
8. Zijdenbos AP, Lerch JP, Bedell BJ, et al (2005) Brain imaging in drug R&D. Biomarkers 10:S58-S68
9. Thompson PM, Hayashi KM, Sowell ER, et al (2004) Mapping cortical change in Alzheimer's disease, brain development, and schizophrenia. Neuroimage 23:S2-S18
10. Thompson PM, Hayashi KM, de Zubicaray G, et al. (2003) Dynamics of gray matter loss in Alzheimer's disease. J Neurosci 23:994-1005
11. Chetelat G, Landeau B, Eustache F (2005) Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study. Neuroimage 27:934-946
12. Frisoni GB, Testa C, Pievani M, et al (2006) ICAD Madrid 14-19 2006
13. Alexander GE, Chen K, Pietrini P, et al (2002) Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry 159:738-745
14. Stefanova E, Wall A, Almkvist O, et al (2006) Longitudinal PET evaluation of cerebral glucose metabolism in rivestigmine treated patients with mild Alzheimer's disease. J Neural Transm 113:205-218
15. Nobili F, Vitali P, Canfora M, et al (2002) Effects of long-term Donepezil therapy on rCBF of Alzheimer's patients. Clin Neurophysiol 113:1241-1248
16. Shimizu S, Hanyu H, Iwamoto T, et al (2006) SPECT follow-up study of cerebral blood flow changes during Donepezil therapy in patients with Alzheimer's disease. J Neuroimaging 16:16-23
17. Fleisher AS, Houston WS, Eyler LT, et al (2005) Identification of Alzheimer disease risk by functional magnetic resonance imaging. Arch Neurol 62:1881-1888
18. Smith CD, Andersen AH, Kryscio RJ (1999) Altered brain activation in cognitively intact individuals at high risk for Alzheimer's disease. Neurology 53:1391-1396
19. Smith CD, Kryscio RJ, Schmitt FA, et al (2005) Longitudinal functional alterations in asymptomatic women at risk for Alzheimer's disease. J Neuroimaging 15:271-277
20. Hock C, Villringer R, Muller-Spahn F, et al (1996) Near infrared spectroscopy in the diagnosis of Alzheimer's disease. Annals of the New York Academy of Sciences 777:22-29
21. Arai H, Takano M, Miyakawa K, et al (2006) A quantitative near-infrared spectroscopy study: a decrease in cerebral haemoglobin oxygenation in Alzheimer's disease and mild cognitive impairment. Brain and Cognition 61: 189-194
22. Archer A, Edison P, Brooks DJ (2006) Amyloid load and cerebral atrophy in Alzheimer's Disease: an 11C-PIB positron emission tomography study. Ann Neurol 60:145-147
23. Edison P, Archer HA, Hinz R, et al (2007) Amyloid, hypometabolism, and cognition in Alzheimer disease. An [11C]PIB and [18F]FDG PET study. Neurology 68:501-508
24. Small GW, Kepe V, Ercoli LM, et al (2006) PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 355:2652-2663
25. Bacskai BJ, Hyman BT (2002) Alzheimer's disease: what multiphoton microscopy teaches us. The neuroscientist 8:386-390
26. Skoch J, Hyman BT, Bacskai BJ (2006) Preclinical characterization of amyloid imaging probes with multiphoton microscopy. J Alzheimers Dis 9:401-407